Moreover, TRAIL serum levels at T1D onset showed an inverse correlation with the insulin requirement at different time points up to 21 months of follow-up (10) and these data were in agreement with an independent study performed on T2D, which showed that circulating levels of TRAIL increased in patients with insulin therapy (13). Here, TNFSF10 is linked to type 2 diabetes mellitus.